Bluejay Diagnostics, Inc. Estimates – NASDAQ:BJDX

Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness

Bluejay Diagnostics Completes Establishment Of Manufacturing Site For Symphony Cartridges, Reaching Contractual Milestone As It Advances Toward Regulatory Submission And Potential Commercialization

Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis Patients

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics Reports SYMON-II Baseline Data Showing Diverse Critically Ill Sepsis Population And Meaningful Mortality Events Supporting IL-6 Evaluation For 28-Day Mortality Risk

Bluejay Diagnostics Federal Healthcare Partnership Builds Commercial Pathway Ahead of FDA Clearance

A medical test company is preparing for about 170 VA medical centers. FDA clearance or authorization comes first.

These stocks are moving in today's pre-market session

$BJDX stock is up 16% today. Here's what we see in our data.

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

BJDX Stock Dips As Pivotal Sepsis Trial Hits Key Milestone

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Why Is Bluejay Diagnostics Stock Soaring Tuesday? - Bluejay Diagnostics (NASDAQ:BJDX)